<DOC>
	<DOCNO>NCT01453348</DOCNO>
	<brief_summary>This study compare safety immunogenicity profile combine hepatitis A/B vaccine give alone concomitantly MenACWY-CRM healthy adult .</brief_summary>
	<brief_title>Study Evaluate Safety Immunogenicity Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Individuals eligible enrollment study female male subject show healthy : 1 . Between 18 64 year age inclusive give write informed consent ; 2 . Available visit telephone call schedule study ; 3 . In good health determine medical history , physical examination clinical judgment investigator ; 4 . For female subject , negative urine pregnancy test . Individuals eligible enrol study : 1. Who breastfeed . 2. Who previous personal history Neisseria meningitidis , hepatitis A hepatitis B infection . 3. Who receive previous immunization meningococcal vaccine . 4. Who receive previous hepatitis A and/or B vaccination , determine history ( interview subject ) and/or review vaccination card , less 5 year elapse since vaccination . 5. Who receive investigational agent vaccine within 30 day prior enrollment expect receive investigational agent vaccine prior completion study . 6. Who receive live license vaccine within 30 day inactive vaccine within 15 day prior enrollment receipt license vaccine anticipate study period ( Exception : Influenza vaccine might administer 15 day prior study immunization le 15 day study immunization ) . 7. Who experience , within 7 day prior enrollment , significant acute infection ( example require systemic antibiotic treatment antiviral therapy ) experience fever ( define body temperature ≥ 38°C ) within 3 day prior enrollment . 8. Who serious acute , chronic progressive disease : History cancer Complicated diabetes mellitus Advanced arteriosclerotic disease Autoimmune disease HIV infection AIDS Blood dyscrasia Congestive heart failure Renal failure Severe malnutrition ( Note : Subjects mild asthma eligible enrollment . Subjects moderate severe asthma require routine use inhale systemic corticosteroid eligible enrollment ) . 9. Who epilepsy , progressive neurological disease history GuillainBarre syndrome . 10. Who history anaphylaxis , serious vaccine reaction , allergy vaccine component , include limited latex allergy antibiotic allergy . 11. Who know suspected impairment/alteration immune function , either congenital acquire result ( example ) : Receipt immunosuppressive therapy within 30 day prior enrollment ( systemic corticosteroid administer 5 day , daily dose &gt; 1 mg/kg/day prednisone equivalent 30 day prior enrollment , cancer chemotherapy ) ; Receipt immunostimulants ; Receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 90 day prior enrollment full length study . 12. Who know bleed diathesis , condition might associate prolonged bleeding time . 13. Who condition , opinion investigator , might interfere evaluation study objective . 14. Who part study personnel close family member conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>meningococcal</keyword>
	<keyword>conjugate</keyword>
	<keyword>vaccine</keyword>
	<keyword>adult</keyword>
</DOC>